NasdaqGS:NVCRMedical Equipment
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition
NovoCure (NVCR) has drawn fresh attention after reporting record 2025 revenues of $655 million, appointing Frank Leonard as CEO, and advancing FDA submissions for its tumor treating fields therapies.
See our latest analysis for NovoCure.
Those record 2025 revenues and the new CEO appointment come after a mixed year in the market, with a 30 day share price return of 6.17% and a 1 year total shareholder return decline of 47.74%. This suggests long term investors are still reassessing risk even...